Board of Directors
The company's Board of Directors maintains three committees: (1) nomination and compensation committee; (2) an audit committee; and (3) a financing strategy and transaction committee. Members of each committee are specified below.
| Name | Position |
| Michael Lytton, JD, MSc 1, 3 | Chairman |
| Hans Peter Hasler 2 | Vice Chairman |
| Jürg Ambühl, PhD 2 | Member |
| Martin Gertsch 2 | Member |
| Timothy Rink, MD, MA, SCD 1, 3 | Member |
| Klaus Schollmeier, PhD | Member |
| Bernd Seizinger, Prof, MD, PhD 1, 3 | Member |
1 Member of the Nomination and Compensation Committee
2 Member of the Audit Committee
3 Member of the Financing Strategy and Transaction Committee
Michael Lytton is Chairman of the Board, its Nomination & Compensation Committee and its Financial Strategy & Transactions Committee. He is Executive Vice President, Corporate and Business Development of Biogen Idec. Mr Lytton holds a JD from Harvard Law School and an MSc in epidemiology and medical statistics from the London School of Hygiene and Tropical Medicine. Read more...
Hans Peter Hasler serves as Chairman of the Board of Directors of HBM BioVentures Ltd. Mr Hasler holds a federal commercial diploma and a marketing manager certificate.
Read more...
Jürg Ambühl is a seasoned marketing specialist with a long track record in the pharmaceutical industry and former partner of Ares Life Sciences AG. He holds a PhD in chemistry from the ETH Swiss Federal Institute of Technology, Zurich, and an MBA from the INSEAD, Fontainebleau, France. Read more...
Martin Gertsch is Chairman of the Audit Committee. He is Chief Financial Officer of Delenex Therapeutics AG, a privately held, new clinical-stage biotechnology company. Mr Gertsch is a certified fiduciary and public accountant. Read more...
Timothy Rink is former Chairman and Chief Executive Officer of Aurora Biosciences. He holds an MA, an MD and ScD, all from the University of Cambridge. Read more...
Klaus Schollmeier is Chief Executive Officer of Santhera. He holds a PhD in biology from the University of Düsseldorf.Read more...
Bernd Seizinger is an independent consultant and former President and Chief Executive Officer of GPC Biotech. He holds an MD from the Ludwig Maximilians University and a PhD from the Max Planck Institute of Psychiatry, both Munich. Read more...